BIOCARTIS GROUP
BE · LEI 549300J4HOJL5KG8HY54 ·
3 bilanci annuali in archivio, esercizi 2021–2023
I numeri principali, anno per anno
| Esercizio | 2023 | 2022 | 2021 |
|---|---|---|---|
| Chiusura | 31/12/2023 | 31/12/2022 | 31/12/2021 |
| Valuta | EUR | EUR | EUR |
| Verifiche contabili | verificato | verificato | verificato |
| Ricaviifrs-full:Revenue | 47 387 000 | 57 481 000 | 48 269 000 |
| Risultato operativoifrs-full:ProfitLossFromOperatingActivities | -41 293 000 | -47 047 000 | -62 645 000 |
| Risultato nettoifrs-full:ProfitLoss | 18 377 000 | -65 381 000 | -71 472 000 |
| Totale attivoifrs-full:Assets | 114 277 000 | 142 480 000 | 210 517 000 |
| Patrimonio nettoifrs-full:Equity | -30 284 000 | -33 897 000 | 36 824 000 |
| Totale passivoifrs-full:Liabilities | — | — | — |
| Scheda completa | Bilancio 2023 | Bilancio 2022 | Bilancio 2021 |
Ogni voce porta sotto l'etichetta il concetto della tassonomia IFRS da cui viene. Gli importi sono quelli depositati, nella valuta del deposito, non convertiti. Un trattino vuol dire che la voce non è stata mappata in quel bilancio, non che valga zero. Lo stato patrimoniale e il conto economico completi, le verifiche una per una e il documento originale sono nella scheda di ciascun bilancio.
Chi è
Testo dell'emittente, citato dal deposito senza modifiche né traduzione. ESEF non contiene una classificazione settoriale: quello che segue è quanto la società dichiara di sé nelle informazioni di identificazione previste dallo IAS 1.138.
| Attività e operazioniifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Sede principale dell'attivitàifrs-full:PrincipalPlaceOfBusiness · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Domicilioifrs-full:DomicileOfEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Paese di costituzioneifrs-full:CountryOfIncorporation · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Forma giuridicaifrs-full:LegalFormOfEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Capogruppo ultimaifrs-full:NameOfUltimateParentOfGroup · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |
| Controllanteifrs-full:NameOfParentEntity · lingua dichiarata en · dal deposito del 2023-12-31 | Notes to the consolidated financial statements General information GENERAL 4Up until the date of the Security Enforcement, Biocartis Group NV, a company incorporated in Belgium with registered address at Generaal de Wittelaan 11 B, 2800 Mechelen, Belgium (the ‘Company’) controlled operating subsidiaries that commercialized a proprietary molecular diagnostics (‘MDx’) platform. The Company had established subsidiaries in Belgium (Biocartis NV), the United States of America (Biocartis Inc.) and Italy (Biocartis SRL) as well as a joint venture in Hong Kong (China) (Wondfo-Cartis Ltd.). Since the date of the Security Enforcement, Biocartis NV, Biocartis Inc. and Biocartis SRL ceased to be subsidiaries of the Company. For sake of clarity, any reference in this document to the ‘Group’ shall, as of the date of the Security Enforcement, not be deemed to include Biocartis NV, Biocartis Inc. and Biocartis Italy SRL. The consolidated financial statements have been authorized for issue on 30 December 2024 by the board of directors of the Company (the ‘Board of Directors’). |